$57.4 M

ZIVO Mkt cap, 08-Jan-2020
Zivo Bioscience Net income (Q3, 2019)-1.8 M
Zivo Bioscience EBIT (Q3, 2019)-1.6 M
Zivo Bioscience Cash, 30-Sept-201915.4 K

Zivo Bioscience Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2018

Revenue

88.9k

Cost of goods sold

138.3k

Gross profit

(49.4k)

Gross profit Margin, %

(56%)

Sales and marketing expense

13.7k198.6k

R&D expense

377.9k677.5k1.0m2.0m1.0m789.0k2.8m

General and administrative expense

603.1k938.2k1.2m907.2k963.3k832.2k1.4m

Operating expense total

1.9m2.1m3.1m8.9m4.7m1.6m4.2m

EBIT

(1.9m)(2.1m)(3.1m)(5.2m)(3.1m)(3.5m)(6.1m)

EBIT margin, %

(2181%)

Interest expense

47.1k141.7k441.5k589.6k35.5k

Interest income

Net Income

(2.7m)(3.2m)(10.1m)680.8k(5.8m)(6.1m)(14.6m)

Zivo Bioscience Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2018

Cash

225.7k47.1k493.1k1.4k16.6k507.0k388.9k

Accounts Receivable

118.5k191.0m

Prepaid Expenses

10.4k8.7k72.1k31.7k12.3k22.6k

Inventories

Current Assets

249.8k90.8k688.5k33.1k28.9k520.4k411.5k

PP&E

83.5k13.2k93.8k68.8k43.8k18.8k

Total Assets

463.5k234.0k2.2m101.9k72.7k737.3k411.5k

Accounts Payable

660.6k938.6k483.2k1.2m1.3m666.4k422.4k

Short-term debt

7.7k1.6m3.6m

Current Liabilities

1.8m3.4m10.9m6.2m5.0m11.2m22.7m

Long-term debt

423.4k593.9k890.8k237.0k4.6m

Non-Current Liabilities

706.7k828.9k890.8k237.0k4.6m

Total Debt

431.1k593.9k2.5m3.9m4.6m

Total Liabilities

2.5m4.2m11.8m6.5m9.6m14.4m22.7m

Common Stock

100.0k105.3k116.9k128.8k132.2k180.0k

Additional Paid-in Capital

27.1m28.4m32.9m35.4m38.1m40.0m56.0m

Retained Earnings

(29.3m)(32.5m)(42.6m)(41.9m)(47.7m)(53.8m)(78.4m)

Total Equity

(2.0m)(4.0m)(9.6m)(6.4m)(9.5m)(13.6m)(22.3m)

Debt to Equity Ratio

-0.2 x-0.2 x-0.3 x-0.6 x-0.5 x

Debt to Assets Ratio

0.9 x2.5 x1.2 x37.9 x63.3 x

Financial Leverage

-0.2 x-0.1 x-0.2 x0 x0 x-0.1 x0 x

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q4, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

10.3k60.1k132.4k95.6k7.3k25.9k254.6k281.2k96.8k31.0k101.6k11.0k16.0k19.9k259.2k25.7k585.3k1.0m24.2k1.2m317.1k98.1k678.0k228.4k4.3k43.5k15.4k

Accounts Receivable

118.5k118.5k118.5k

Prepaid Expenses

16.5k38.9k37.7k19.4k36.7k87.3k97.4k89.6k37.5k25.1k109.5k47.0k31.9k52.9k33.9k29.3k48.7k33.2k90.8k15.1k89.2k61.7k50.1k99.5k68.7k54.5k

Inventories

34.0k15.7k

Current Assets

62.8k92.4k180.7k173.4k62.5k97.5k495.4k519.0k304.9k68.5k126.6k120.5k63.0k51.8k312.1k59.6k614.5k1.1m57.4k1.3m332.3k187.3k739.7k278.5k103.8k112.2k69.9k

PP&E

159.9k124.8k65.6k52.5k36.2k100.0k87.5k81.3k75.0k62.5k56.3k50.0k37.5k31.3k25.0k12.5k6.3k

Total Assets

390.8k366.1k417.4k356.3k228.9k221.2k496.2k2.0m1.8m1.5m1.6m183.0k119.2k101.8k349.6k90.8k749.9k1.2m205.5k1.4m4.2m2.8m739.7k278.5k103.8k112.2k69.9k

Accounts Payable

609.4k655.5k723.0k874.7k915.0k802.5k938.8k600.4k682.4k483.0k1.4m1.2m1.2m1.3m1.1m823.7k769.1k760.1k635.0k541.7k1.1m450.4k393.1k802.8k1.2m962.2k

Short-term debt

14.0k595.01.3m1.5m1.6m2.2m2.8m3.9m4.1m4.9m1.7m2.2m2.4m240.0k

Current Liabilities

858.6k1.0m2.1m2.5m2.5m4.6m8.7m12.0m5.7m5.9m9.2m6.9m7.2m8.3m5.6m6.3m6.7m2.5m2.6m18.8m4.6m5.8m19.6m21.9m24.8m11.3m11.0m

Long-term debt

255.2k281.1k565.0k719.0k885.6k399.4k542.7k1.0m636.1k481.4k645.8k881.0k441.9k4.9m4.9m6.8m14.1m

Non-Current Liabilities

636.1k653.8k818.1k966.2k1.1m478.1k399.4k542.7k1.0m636.1k481.4k645.8k881.0k441.9k4.9m4.9m6.8m14.1m14.2m650.0k16.0m16.5m

Total Debt

269.2k281.7k565.0k719.0k885.6k1.7m2.1m2.6m2.8m3.3m4.5m5.0m5.4m6.5m7.1m9.2m14.3m

Total Liabilities

1.5m1.7m2.9m3.5m3.6m5.1m9.1m12.5m6.7m6.5m9.6m7.5m8.1m8.8m10.5m11.2m13.5m16.6m16.8m19.5m20.5m22.3m19.6m21.9m24.8m11.3m11.0m

Common Stock

96.6k97.8k100.0k100.4k103.2k105.3k107.8k113.6k122.9k127.3k128.6k129.9k130.9k131.9k132.7k132.8k136.6k137.4k139.3k140.9k141.1k141.3k160.3k168.5k186.2k341.7k357.8k

Additional Paid-in Capital

26.1m26.5m27.8m27.8m28.2m28.5m29.5m32.2m33.6m34.2m34.5m35.7m37.1m37.9m38.9m40.2m39.6m40.2m40.4m41.8m47.4m48.0m52.2m53.6m56.6m72.5m74.6m

Retained Earnings

(27.3m)(27.9m)(30.3m)(31.1m)(31.6m)(33.4m)(38.2m)(42.9m)(38.6m)(39.3m)(42.7m)(43.2m)(45.2m)(46.7m)(49.1m)(51.4m)(52.5m)(55.6m)(57.1m)(59.9m)(63.8m)(67.7m)(71.2m)(75.4m)(81.5m)(84.0m)(85.8m)

Total Equity

(1.1m)(1.3m)(2.5m)(3.1m)(3.3m)(4.9m)(8.6m)(10.5m)(4.9m)(5.0m)(8.0m)(7.4m)(8.0m)(8.7m)(10.1m)(11.1m)(12.8m)(15.3m)(16.6m)(18.0m)(16.3m)(19.6m)(18.8m)(21.6m)(24.7m)(11.2m)(10.9m)

Debt to Equity Ratio

-0.2 x-0.2 x-0.2 x-0.2 x-0.3 x-0.2 x-0.2 x-0.5 x-0.6 x-0.4 x-0.6 x-0.6 x-0.6 x-0.6 x-0.6 x-0.7 x-0.9 x

Debt to Assets Ratio

0.7 x0.8 x1.4 x2 x3.9 x3.3 x1 x1.4 x1.8 x2.1 x24.8 x41.5 x52.8 x18.7 x78.3 x12.3 x11.5 x

Financial Leverage

-0.4 x-0.3 x-0.2 x-0.1 x-0.1 x0 x-0.1 x-0.2 x-0.4 x-0.3 x-0.2 x0 x0 x0 x0 x0 x-0.1 x-0.1 x0 x-0.1 x-0.3 x-0.1 x0 x0 x0 x0 x0 x

Zivo Bioscience Cash Flow

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2018

Net Income

(2.7m)(3.2m)(10.1m)680.8k(5.8m)(6.1m)(14.6m)

Depreciation and Amortization

967.073.8k19.5k25.0k25.0k25.0k

Inventories

(10.6k)

Accounts Payable

205.0k278.1k(455.4k)744.3k100.1k(448.1k)(119.3k)

Cash From Operating Activities

(1.3m)(1.8m)(2.7m)(2.3m)(2.5m)(5.0m)

Purchases of PP&E

4.7k3.5k

Cash From Investing Activities

(4.7k)(3.5k)

Short-term Borrowings

Cash From Financing Activities

1.5m1.6m3.8m2.2m2.3m3.0m5.1m

Net Change in Cash

210.1k(178.5k)(491.7k)15.2k490.4k71.8k

Interest Paid

7.3k

Income Taxes Paid

50.0

Quarterly